通产丽星(002243.SZ):子公司拟发行不超16亿元公司债券
格隆汇5月28日丨通产丽星(002243.SZ)公布,为满足公司全资子公司力合科创集团有限公司(“力合科创”)生产经营及战略发展的资金需求、降低融资成本,结合力合科创实际经营情况等因素,力合科创拟公开发行公司债券和注册发行债务融资工具。
此次公开发行公司债券的发行规模合计不超过人民币16亿元(含16亿元)。具体发行规模根据国家法律、法规及证券监管部门的有关规定,根据力合科创资金需求情况和发行时的市场情况,在上述范围内确定。
募集资金扣除发行费用后可用于偿还有息债务、补充营运资金、对外投资等一种或多种用途或其他用途,具体募集资金用途由力合科创根据实际资金需求情况确定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.